A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy

Published: Oct 25, 2019
Abstract
T-cell-based immunotherapy strategies have profoundly improved the clinical management of several solid tumors and hematological malignancies. A recently developed and promising immunotherapy approach is to redirect polyclonal MHC-unrestricted T lymphocytes toward cancer cells by bispecific antibodies (bsAbs) that engage the CD3 complex and a tumor-associated antigen (TAA). The TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) is an...
Paper Details
Title
A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy
Published Date
Oct 25, 2019
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.